Hologic Inc Stock Price, News & Analysis

Hologic (Nasdaq: HOLX) is presenting groundbreaking research on its AI-powered mammography technology at the European Society of Breast Imaging (EUSOBI) Annual Scientific Meeting in Scotland. Two significant studies demonstrate the technology's capabilities:

The first study at Massachusetts General Hospital analyzed 600 biopsy-proven cancer cases using Hologic's Genius AI Detection 2.0. Results showed higher AI case scores correlated with more aggressive tumors and node-positive cancers. The second study compared AI performance against 108 radiologists reviewing 75 challenging breast cancer cases, with AI showing similar cancer detection rates but higher sensitivity.

Additionally, Hologic is showcasing its Sentimag Gen 3 device for tumor localization and breast cancer staging at EUSOBI, recently launched in Europe following the Endomag acquisition.

[ "AI technology demonstrated comparable performance to radiologists in cancer detection", "AI system showed potential to identify more aggressive cancers earlier", "New Sentimag Gen 3 device expands company's breast surgery portfolio in Europe", "Technology could help address radiologist workforce shortages in mammogram screening" ]

Hologic (Nasdaq: HOLX), a medical technology company focused on women's health, announced its participation in the 23rd Annual Morgan Stanley Global Healthcare Conference. The company will present a fireside chat on September 9th at 10:45 a.m. Eastern Time in New York.

The presentation will be accessible through a live webcast on the investors section of Hologic's website, with the recording remaining available for 30 days following the event.

Hologic (NASDAQ:HOLX) reported strong fiscal Q3 2025 results, with revenue of $1,023.8 million, up 1.2% year-over-year and exceeding guidance. The company delivered GAAP EPS of $0.86 (up 4.9%) and non-GAAP EPS of $1.08 (up 1.9%), surpassing guidance.

Key divisional performance included Diagnostics revenue of $448.9 million (up 1.8%), Breast Health revenue of $365.2 million (down 5.1%), and Surgical revenue of $178.4 million (up 7.1%). The company generated strong cash flow from operations of $343.2 million and successfully refinanced its credit facility with a new $1.17 billion term loan and $1.25 billion revolver.

For Q4 2025, Hologic expects revenue of $1,030-$1,040 million with non-GAAP EPS of $1.09-$1.12, projecting continued growth momentum.

Hologic (NASDAQ: HOLX), a medical technology company focused on women's health, has scheduled its third quarter fiscal 2025 financial results announcement for Wednesday, July 30, 2025, after market close.

The company will host a conference call at 4:30 p.m. Eastern Time on the same day. Participants can join via phone using specific dial-in numbers or through a webcast. A replay will be available on Hologic's investor relations website for 30 days following the call.

Hologic (NASDAQ: HOLX) announced new data on their Breast Cancer Index® (BCI®) test to be presented at ASCO 2025. The study, analyzing over 2,800 patients, demonstrates the test's significant impact in guiding extended endocrine therapy decisions for early-stage, hormone receptor-positive breast cancer patients. Key findings show that BCI testing changed treatment recommendations in approximately 40% of cases, while increasing physician confidence and patient comfort in treatment decisions. The BCI test is notably the only genomic test recognized by clinical guidelines for informing extended endocrine therapy decisions. Two presentations at ASCO will showcase the BCI Registry Study results and translational data from the TEXT trial, validating the test's ability to assess recurrence risk in premenopausal women.

Hologic (NASDAQ: HOLX) has announced its participation in three major upcoming investor conferences in May and June 2025. The company will present at: the 2025 RBC Capital Markets Global Healthcare Conference in New York on May 20 at 9:30 a.m. ET, William Blair's 45th Annual Growth Stock Conference in Chicago on June 4 at 4 p.m. CT, and the Jefferies Global Healthcare Conference 2025 in New York on June 5 at 11:05 a.m. ET.

All presentations will be accessible through live webcasts via the investors section of Hologic's website, with recordings remaining available for 30 days after each event.

Hologic (HOLX) reported Q2 FY2025 financial results with revenue of $1,005.3 million, slightly exceeding guidance but decreasing (1.2%) year-over-year. The company posted a GAAP diluted EPS loss of ($0.08) compared to $0.72 in the prior year, primarily due to $220.9 million in non-cash impairment charges. Non-GAAP EPS remained flat at $1.03. Key segment performance: - Diagnostics revenue: $453.6M (+0.8%) - Breast Health revenue: $356.2M (-7.4%) - Surgical revenue: $162.5M (+4.2%) - Skeletal health: $33.0M (+21.8%) The company maintained its full-year revenue guidance of $4,050-$4,100 million but lowered both GAAP and non-GAAP EPS guidance due to tariffs and geopolitical conditions. During Q2, Hologic repurchased 3.0 million shares for $200 million and ended with $1.43 billion in cash and cash equivalents.

Hologic (NASDAQ: HOLX) is presenting groundbreaking research on its AI-powered mammography technology at the Society of Breast Imaging Annual Symposium in Colorado Springs. A key study conducted at Massachusetts General Hospital analyzed 5,000 digital breast tomosynthesis screening exams using Hologic's Genius AI® Detection 2.0 solution.

The research examined 100 cancer cases initially missed by radiologists but later confirmed malignant, along with 500 previously identified cancers. The company is also showcasing its new Genius AI Detection PRO solution, which features a color-coded system for cancer detection confidence and has demonstrated up to 24% reduction in radiologists' reading time.

Additional highlights include the Envision™ Mammography Platform and contrast-enhanced mammography technology. The symposium includes informational sessions on implementing contrast-enhanced mammography and integrating AI into mammography practices.

Hologic (NASDAQ: HOLX) has released its 2024 sustainability report, highlighting significant progress in women's health initiatives and environmental commitments. The company's technologies impacted over 193 million lives worldwide in 2024, with major achievements including FDA clearance for the Genius™ Digital Diagnostics System and launch of Genius AI® Detection 2.0 for cancer screening.

Key environmental milestones include a commitment to 50% emissions reduction by 2030 and net zero by 2050, with a 10% emission reduction already achieved across Scopes 1, 2, and 3 since 2020. The company has reduced water usage by 20% at key sites and diverted 65% of waste from landfills.

Notable social achievements include maintaining a zero gender net pay gap, 97th percentile employee engagement, and $1.8M in corporate grants. The company expanded partnerships with organizations like the Black Women's Health Imperative and launched the fourth Global Women's Health Index with Gallup, covering 97% of the global adult population.